Background. Routine mood screening is recommended after stroke. However, clinicians report difficulty selecting appropriate tools from the wide range available. We aimed to systematically review the psychometric properties and clinical utility of mood screening tools for stroke survivors.
Introduction
Around a third of stroke survivors suffer from low mood, with about 10% receiving a diagnosis of major depression and many experiencing co-morbid anxiety (House et al. 1991; Ayerbe et al. 2013) . Mood disturbance has been linked to greater dependence in activities of daily living, institutionalization and mortality, and poorer quality of life (Kotila et al. 1999; House et al. 2001; Pohjasvaara et al. 2001; Williams et al. 2004; Donnellan et al. 2010) . However, the management of mood disorders post-stroke is often suboptimal; problems are frequently undiagnosed and inadequately treated (Hackett et al. 2005 ) and most survivors report insufficient help to deal with their emotional needs (National Audit Office, 2010) . This may result from difficulties in professionals' recognition of the symptoms of low mood in patients with stroke because of the overlap between stroke-related impairments, hospitalization and somatic symptoms of mood disorder (Hart & Morris, 2007) .
In acknowledgement of this shortcoming, improving management and access to psychological services has become a priority (NHS Improvement, 2011) . Timely diagnosis is an essential element, facilitating early access to treatment and improving prognosis (Jorge et al. 2003; Mitchell et al. 2009 ); thus, clinical guidelines recommend that stroke survivors should be routinely screened for the presence of mood disorders, using a validated tool (National Stroke Foundation, 2010; NICE, 2010) . Screening rates have improved substantially over the past decade (Bowen et al. 2005 ; National Audit Office, 2010) but 20% of appropriate patients are still not screened (NSSA, 2011) . One issue that affects implementation of the guidelines is the choice of screening tool; clinicians report that lack of knowledge and consensus about the best measures to use are barriers (Burton et al. 2013) . As part of an ongoing programme of work to select and implement effective measurement tools in stroke rehabilitation, we aimed to systematically review the psychometric properties of tools to screen for mood disorders poststroke to identify the most suitable for clinical practice. To facilitate uptake in clinical practice, we also aimed to identify optimal cut-off scores for major and any degree of depression and anxiety, and assess clinical utility (or feasibility).
Method

Study identification and selection
Electronic databases (AMED, PsycINFO, CINAHL, Medline and EMBASE) were searched from their inception to May 2013, using the following keywords: stroke OR cerebrovascular accident OR CVA and screen* OR tool OR measure* OR questionnaire OR scale AND mood OR depression OR anxiety OR emotion OR distress. All searches were limited to English language and human studies.
We also searched the reference lists of selected articles, previously published reviews and the Stroke Group of the Cochrane Library. The titles, abstracts and then full texts were screened by two independent reviewers to identify articles that reported validation of tools to screen for low mood, distress and/or anxiety in people with stroke. Articles that assessed the properties of mood screening tools, reported both sensitivity and specificity compared with a gold standard measure and aimed to identify people who needed further evaluation or treatment were selected. We excluded studies of tools that were not designed as a screening tool and intended to make a full assessment of mood or diagnosis, including the Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery & Asberg, 1979) , the Hamilton Rating Scale for Depression (HAMD; Hamilton, 1960) , the Cornell Scale (Alexopoulos et al. 1988) , the Geriatric Mental State Examination (GMS; Copeland et al. 1987) , the PostStroke Depression Rating Scale (PSDS; Gainotti et al. 1997 ) and the Symptom Checklist 90 (SCL-90; Derogatis et al. 1973) . We also excluded studies of tools that assessed generic related constructs such as quality of life; merely involved the validation of a language translation of a tool; were conference papers or abstracts where the data could not be extracted; and where less than 50% of the participants had suffered a stroke or data from people with stroke could not be extracted.
Data extraction
We extracted independently from the selected articles data regarding the participant samples and settings (where available), selection criteria, tools evaluated, type of disorder assessed, and sensitivity and specificity. Cut-off scores for major depression and any degree of depression and anxiety were identified. Positive (PPV) and negative predictive values (NPV) at each cut-off score were calculated from available data where possible. Final data were agreed by consensus with a third party to arbitrate if necessary. Sensitivity 50.8 and specificity 50.6 were considered sufficiently accurate. There is often a trade-off between sensitivity and specificity and these (widely used) criteria are considered appropriate for clinical practice, where the costs of failing to identify an individual with difficulties are greater than the costs of further evaluation of those who may not require treatment .
Any cut-off score that did not yield data meeting these criteria in at least one study was excluded and any tools that did not report any cut-off scores with sufficient sensitivity and specificity were rejected.
Tools that met these criteria were then assessed for clinical utility (the feasibility of using a tool in clinical practice) from the original articles (where possible), marketing material (including costs), the tools' authors and instruction manuals. A previously published tool to assess clinical utility of outcome measures (Connell & Tyson, 2012 ) was reviewed and adapted by a consultation group of occupational therapists and clinical psychologists working in stroke services in a large UK conurbation to reflect their priorities for selecting screening tools. These are summarized as follows: as access to clinical psychology is limited for most stroke survivors, it is important that screening tools can be completed by any member of the multidisciplinary team to identify moderate to severe difficulties for onward referral (NSSA, 2008) . This is often undertaken in addition to their traditional workload so screening tools need to be quick and easy to administer, with minimal training requirements. Finally, they need to be inexpensive or, preferably, freely available, particularly because, in the current financial climate, a cheaper tool would be chosen over one incurring costs if it performed equally well in terms of psychometrics.
The final utility criteria and scores were:
(a) Time to administer and score the measure: 45 min (score 2); 6-10 min (score 1); 511 min (score 0). (b) Initial costs for purchase of the measure (e.g. starter kit including manual): 2 = freely available; 1 = cost < £100; 0 = cost 5£100 or unavailable. (c) Additional cost per record form: 1 = no additional costs; 0 = additional cost or unavailable.
(d) Need for specialist training to administer and score the measure: 1 = no specialist training required; 0 = specialist training required.
Summing these scores gave a maximum of six points, with higher scores indicating greater clinical utility. Tools that scored < 6 were rejected at this stage.
Results
The searches revealed 30 papers that met the selection criteria, involving 3751 stroke survivors and 27 screening tools. All 27 tools were tested to detect depression and eight were also used to identify anxiety. The tools' progress through the review is summarized in Fig. 1 and detailed below. The selected tools are described in Table 1 and details of the population tested are presented in Table 2 . Most of the selected papers recruited their participants through acute admissions to hospital (Parikh et al. 1988; Williams et al. 2005; Lightbody et al. 2007; Healey et al. 2008; Lee et al. 2008; Hacker et al. 2010; de Man-van Ginkel et al. 2012a; Kang et al. 2012) , often consecutively (Watkins et al. 2001a (Watkins et al. ,b, 2007 Aben et al. 2002; Benaim et al. 2004; Tang et al. 2004a; Berg et al. 2009; Sagen et al. 2009; de Man-van Ginkel et al. 2012b; Tham et al. 2012) . Others recruited from in-patient rehabilitation facilities (Tang et al. 2004b,c; TurnerStokes et al. 2005; Roger & Johnson-Greene, 2009; de Man-van Ginkel et al. 2012a) , or a mixed in-patient and community-dwelling population (Shinar et al. 1986; Lincoln et al. 2003; Sivrioglu et al. 2009; Turner et al. 2012) ; only one study recruited solely in the community (Agrell & Dehlin, 1989) . Three studies involved participants who were also taking part in a clinical trial (O'Rourke et al. 1998; Lincoln et al. 2003; Williams et al. 2005) . Most assessments were made in the acute (within 1 month) (Shinar et al. 1986; Watkins et al. 2001a Watkins et al. ,b, 2007 Aben et al. 2002; Tang et al. 2004b,c; Lightbody et al. 2007; Lee et al. 2008; Berg et al. 2009; Roger & Johnson-Greene, 2009; Hacker et al. 2010; Kang et al. 2012) or subacute (from 1 to 6 months) stages post-stroke (Johnson et al. 1995; O'Rourke et al. 1998; Tang et al. 2004a; Turner-Stokes et al. 2005; Williams et al. 2005; Watkins et al. 2007; Healey et al. 2008; Berg et al. 2009; Sagen et al. 2009; de Man-van Ginkel et al. 2012a,b) . Five papers considered mood disorders in the long term (more than 6 months) after stroke (Agrell & Dehlin, 1989; Berg et al. 2009; Sivrioglu et al. 2009; Kang et al. 2012; Turner et al. 2012) and one study combined assessment scores of participants between 1 week and 2 years post-stroke (Parikh et al. 1988 ).
communication problems (n = 7): the Brief Assessment Schedule Depression Cards (BASDEC; Adshead et al. 1992) , the Depression Intensity Scale Circles (DISCs; Turner-Stokes et al. 2005) , the distress thermometer (Holland et al. 2011 ), the Numbered Graphic Rating Scale (NGRS; TurnerStokes et al. 2005) , 'smiley faces' (Lee et al. 2008) , Visual Analogue Mood Scales (VAMS) 'sad item' (Stern, 1997) and Visual Analogue Self-Esteem Scales (VASES; Brumfitt & Sheeran, 1999 GHQ-28 (Goldberg & Williams, 1988) Self-report. Patients choose one of four statements for 28 items regarding symptoms of distress over the past 2 weeks, scored on a three-point scale, which is totalled to give a maximum of 84 points. Alternatively, a binary method ('not at all' = 0, 'more than usual' = 1) with a maximum of 28 points. Includes somatic symptoms Self-report <5 No Must be purchased: > £100 for user guide plus record forms
Ongoing costs for record forms Lincoln et al. 2000) and its 10-item version (SADQ-H10; Lincoln et al. 2000) , and the Signs of Depression Scale (SoDS; Hammond et al. 2000) .
The sensitivity and specificity for each cut-off score for the depression screening tools are detailed in Table 2 . Eleven tools did not meet sensitivity and specificity criteria at any cut-off scores and were rejected (see Fig. 1 ). This left 16 tools that could accurately detect depression in people with stroke. Ten were verbal self-report tools, two used visual aids and four were observational measures; these are described briefly in the following sections.
Verbal self-report tools
The verbal self-report tools were all questionnaires completed by the person with stroke or verbally by interview with a health-care professional, apart from the single-question 'Yale' tool (Lachs et al. 1990; Mahoney et al. 1994) , which was reported verbally. All were developed to identify problems in a general population and subsequently applied to stroke.
The questionnaires ranged from two (PHQ-2) to 30 questions (GDS). Five used four-or five-point Likert scales for people to rate the severity or frequency of their symptoms (GHQ-28, HADS, PHQ-2, PHQ-9 and CES-D). Three used a 'yes/no' response format (GDS, GDS-15 and Yale question) whereas the BDI and its second edition BDI-II included four multiple choice statements that graded symptom severity. Most scales were designed to detect depression alone; exceptions were the GHQ-28, which is a measure of general distress, and the HADS, which includes separate scales for depression and anxiety. The time scale over which people rated their mood varied: present mood state (Yale question), the previous week (BDI, CES-D, GDS, GDS-15 and HADS) and the past 2 weeks (BDI-II, GHQ-28, PHQ-2 and PHQ-9) in line with DSM (APA, 1987 (APA, , 1994 (APA, , 2000 . Most tools include somatic items (BDI, BDI-II, CES-D, GHQ-28 and PHQ-9) whereas others seek to limit their inclusion (GDS and GDS-15) or omit them completely (HADS, PHQ-2 and Yale). Screening for mood disorders after stroke 9 'true' and 'false' piles to describe their present mood state. The VAMS 'sad item' involves a vertical line with a cartoon sad face at one end with a verbal descriptor and a neutral face at the opposite end. The person points to where they see themselves on the scale at the present time. Neither measure incorporated somatic symptoms of low mood.
Tools incorporating visual aids
Observational measures
Four observational measures were identified for use with people who could not self-report. The SADQ-H and the SADQ-H10 require an observer to rate the frequency of behaviours related to low mood over the previous week, using a four-point Likert scale, with elevated scores on two consecutive weeks suggesting low mood. The SoDS requires the observer to rate the presence of behaviours related to low mood over the previous week in a 'yes/no' response format. The ADRS uses an interview with, or observation of, the person to indicate severity. All of the measures except for the SoDS incorporated somatic mood-related symptoms.
Optimal cut-off scores
Having selected screening tools that could accurately identify depression, the optimal cut-off score to detect either major depression or any depressive disorder was explored (Tables 3 and 4) . Sufficient data were available for only four verbal screening tools to identify effective cut-off scores for both major depression and any depressive disorder (BDI, GHQ-28, HADS total score and HADS depression subscale). Of the observational tools and those incorporating visual prompts, only the ADRS, BASDEC, SADQ-H and VAMS 'sad item' demonstrated effective cut-off scores although no distinction was made between severity of depression. For all tools, data were reported for multiple cut-off scores, but the results were so highly varied that optimal cut-off scores could not be identified for any of them.
Clinical utility
The 16 selected screening tools were then assessed for clinical utility (Table 1 ). All of the tools took less than 15 min to administer; however, some of the reported administration times were not specific for people with stroke, who often have communication and cognitive problems and may therefore take longer to complete the mood screen. All except the ADRS could be administered without specialist training, but the time needed to complete this tool could not be ascertained. and the Yale question), one (BDI-II) required the purchase of an initial starter kit, which costs under £100 (approximately US$150), whereas the three other tools cost over £100 (GHQ-28, HADS and VAMS). All tools that incurred costs for initial purchase also generated additional costs per person screened, either for paper record forms or for electronic reports. Two tools (BASDEC and BDI) were not available for use. Seven tools met all clinical utility criteria (see Fig. 1 ): four verbal measures (PHQ-2, PHQ-9, GDS-15 and Yale) and three observational measures (SADQ-H, SADQ-H10 and SoDS). None of the tools that incorporated visual prompts to aid self-report met the clinical utility criteria (Table 5) .
Screening for anxiety
Eight screening tools tested to detect anxiety poststroke were identified: three were verbal tools (GDS, GHQ-28 and HADS), three were observational (SADQ-H, SADQ-H10 and SoDS) and two used visual analogue scales (VAMS and VASES; Fig. 1 ). Only the HADS anxiety subscale was designed specifically to measure anxiety, although the total HADS has also been used and these were the only measures to yield adequate sensitivity and specificity data at any cutpoint (Table 4) . None of the visual analogue scales or observational measures met selection criteria.
Clinical utility
Clinical utility for the HADS is mixed (Table 1) : it can be administered in under 5 min with minimal training for staff, but it incurs both initial and recurrent costs and therefore does not meet clinical utility criteria.
Discussion
Our extensive search strategies identified a wide range of tools to screen for mood disorders after stroke, but only the SADQ-H met both the psychometric and clinical utility criteria for both major depression and any depressive disorder; none of the tools incorporating verbal self-report or visual aids met all these criteria. The HADS, BDI, ADRS, BASDEC, GHQ-28 and VAMS 'sad item' all yielded good psychometric data for both major depression and any depressive disorder, indicating that they could accurately identify stroke survivors who needed further assessment and possibly treatment for depression. However, the BASDEC and the BDI are currently unavailable, the former could not be located and the latter was superseded by BDI-II; the other tools incur financial costs (although 'pirate' copies can be downloaded from the internet), require specialist training and/or are timeconsuming to administer. Two tools met the clinical PHQ-2 de Man-van Ginkel et al. Cut-off scores with at least one study reporting 80% sensitivity and 60% specificity criteria have been included. Where no studies reached the sensitivity and specificity criteria at a cut-off score, the cut-off score has been removed. Sensitivity and specificity levels that reach the selection criteria are highlighted in bold.
utility criteria and yielded acceptable psychometrics at a specific cut-off score for either major depression or any depressive disorder; the GDS-15 can detect any depressive disorder (but not specifically major depression) and so may be best used as an initial screen to identify people with stroke who require further evaluation. The PHQ-9 can detect major depression although sensitivity drops to 78% in identifying milder symptoms (Williams et al. 2005) . The HADS (both total score and anxiety subscale) was the only effective tool to identify anxiety, but it does incur a financial cost. There has only been one previous systematic review of screening tools for depression after stroke and this focused on the detection of major depression only (Meader et al. 2014) . One of our objectives in this study was to enable implementation of screening tools by identifying optimal cut-off scores for the tools we could recommend. However, this proved impossible because of the heterogeneity of participant characteristics, study designs and observed sensitivity and specificity estimates. Some of the heterogeneity was due to the varied choice of criterion measures against which the accuracy of the screening tools was judged. A semi-structured interview by a psychiatrist is widely accepted as the 'gold standard' reference criterion but use of different interview tools and diagnostic criteria can result in variances in diagnostic accuracy. The variability and accuracy of these tools will affect the reported accuracy of the screening tools against which they are measured. More consistent use of a criterion measure would enhance metaanalysis and comparison between tools.
A limitation of the psychiatric interview and diagnostic tools is that they are difficult for people with communication and cognitive difficulties to complete. Subsequently, many studies have used other screening tools as the criterion measure (Watkins et al. 2001a (Watkins et al. ,b, 2007 Lee et al. 2008; Hacker et al. 2010; de Man-van Ginkel et al. 2012a) or excluded Cut-off scores with at least one study reporting 80% sensitivity and 60% specificity criteria have been included. Where no studies reached the sensitivity and specificity criteria at a cut-off score, the cut-off score has been removed. Sensitivity and specificity levels that reach the selection criteria are highlighted in bold. HADS, Hospital Anxiety and Depression Scale. Cut-off scores with at least one study meeting 80% sensitivity and 60% specificity criteria have been included. Where no studies reached the sensitivity and specificity criteria at a cut-off score, the cut-off score has been removed. Sensitivity and specificity that reach selection criteria are highlighted in bold.
people with these problems (even those that tested observational tools for people unable to self-report), making the assumption that the results from more able populations would generalize to people with stroke. There is limited evidence to support or refute this assumption. Communication and cognitive problems are common after stroke and their exclusion limits the generalizability and relevance of the findings to clinical practice. Further research is needed involving pragmatic samples of people with stroke at all stages of recovery and survivorship, using predefined cut-off scores to establish the optimal thresholds so that people with both major and mild disorders can be identified.
Most of the selected tools were originally developed for a psychiatric population and then applied to stroke survivors, assuming that the experience of mood disorder after stroke has the same construct as other populations. Although stroke survivors display similar distributions of symptoms scores as people with other physical illnesses (House et al. 1991) , mood disorders may be experienced differently in someone with additional physical or cognitive impairments (Gainotti et al. 1999) . It is a matter of modern health policy that measurement tools should reflect the issues that are important and relevant to service users (so-called patient-reported outcome measures) (Darzi, 2008) and service users' views and expertise should be involved in all levels of research. Thus, it is notable that none of the selected screening tools included stroke survivors' perspectives in their construction and, although they have apparent face validity, the content validity for stroke survivors is unknown.
The inclusion of somatic items in the mood screening tools is particularly controversial because these can overlap with symptoms of stroke and/or effects of being in hospital. For example, many included items assess fatigue, concentration and memory problems or altered activity or sleeping patterns, which are common impairments after stroke independent of any emotional difficulties or hospitalization. Inclusion of such items would conflate the scores and might lead to ineffective clinical decision making or inaccurate research conclusions. To avoid the confounding effects of somatic items, some screening tools exclude them; however, the impact is unclear as there is some evidence that somatic symptoms are among the best differentiators between stroke survivors with and without depression (de Coster et al. 2005) . It might be better to adjust the cut-off scores to reflect the increase in prevalence of these symptoms in the stroke population. Further research is required to investigate the construct of post-stroke depression and anxiety and to establish the content validity of the screening tools for stroke survivors.
A related issue is the construct validity of the screening tools for stroke survivors. Most selected tools were developed using classic test theory and are scored by summing the scores from the different items to produce a 'total' score. This is a controversial approach; many proponents of item response theory would consider this an inappropriate use of categorical data that could produce misleading scores (Tennant & Conaghan, 2007) . Three of the selected tools have been subjected to Rasch analysis in relatively small samples: the BDI-II, GDS and HADS depression subscale. They report inconsistent findings regarding the unidimensionality of the tools and all identified redundant or disordered items, or ineffective scoring methods that did not fit the model (Pickard et al. 2006; Tang et al. 2007; Siegert et al. 2010) . Only one of the studies provided data to enable the ordinal scoring data to be transformed into interval level data to allow use of parametric statistics and change scores to be calculated (Siegert et al. 2010) , and it remains a moot point whether this makes an important difference to the data and how they are reported. Further development of the tools should include Rasch analysis to ensure an effective and efficient scale structure.
Most of the selected tools rely on the person's ability to self-report their mood, which is often compromised after stroke. In an attempt to overcome this, several tools use visual aids to facilitate non-verbal responses. However, these are based on the assumption that stroke survivors are able to interpret the visual aids. Work applying visual aids in tools to measure pain suggests that many stroke survivors, particularly those with right-hemisphere damage, find this difficult (Benaim et al. 2007) . Acceptability and clinical utility of these tools need to be examined with people with stroke with different types and severity of impairment.
Finally, we identified a wide range of tools to detect depression in stroke survivors, but there are few standardized tools to detect anxiety and emotionalism. Further work is needed to develop person-centred tools for these purposes.
Limitations
A limitation of this study is that the quality is dependent on the articles identified. There is evidence of selection bias in the two studies that excluded participants who did not report low mood (Lincoln et al. 2003; Williams et al. 2005) , thereby artificially increasing the prevalence of depression in the sample and probably affecting the reported PPV and NPV. We also included studies from around the world and note that the construct of depression could vary in different cultures, such as collectivist societies, which may have contributed to the heterogeneity of cut-off scores.
Furthermore, we only included published English language studies and so may have missed relevant publications in other languages or unpublished data. To produce a generalizable result, we included studies that assessed stroke survivors at all stages of recovery, from the acute hospital setting to several years poststroke. This may have contributed to our difficulties in ascertaining the optimum cut-off score for each tool, as sensitivity and specificity values at different cut-offs have been demonstrated to vary over time in the period following stroke (Berg et al. 2009 ). Finally, although we used recommended sensitivity and specificity criteria to reflect clinical priorities, alternative criteria may be warranted in different situations; for example, higher specificity may be required where resources for further assessment are limited. Further research should examine and compare the factor structure of depression globally and at different stages poststroke to identify the most effective tools for each situation.
Clinical utility is rarely considered in tool development although it is key to uptake in clinical practice and research. We worked with clinicians in a range of stroke services in one of the largest conurbations in the UK to develop our measure of clinical utility, so we are confident that it is representative of the issues that limit implementation in the UK, at least. However, although the barriers to implementing tools in practice are fairly universal, the cut-off points may be context specific. Different models of health care may have different funding limits or time available for assessment. A further limitation is our reliance on reported administration times within the general population, as there were few reports within a stroke population. It is likely that screening tools would take longer to administer with patients with strokerelated impairments and activity limitations so the reported administration times may be underestimates. To address this, we contacted the authors or publishers of the selected tools for further information regarding clinical utility, but the information was not always available and should be considered a limitation.
Conclusions
The following tools can accurately screen for depression in stroke survivors in clinical practice: the GDS-15 can detect any depressive disorder and the PHQ-9 can detect severe depression whereas the SADQ-H can be used with stroke survivors who are unable to self-report. The HADS (both the total scale and the anxiety subscale) can effectively identify anxiety post-stroke but clinical utility is limited by the costs involved. We were unable to establish the optimal cutoff scores for these or the other selected tools.
